See Also: Facial Wasting, Fat Loss, and HIV; and Wasting Syndrome (Unwanted Weight Loss) and Frailty
General Information
- Body Shape Changes (Lipodystrophy) (AIDS InfoNet) and Spanish version
- Changes to Your Face and Body (Lipodystrophy and Wasting) (Poz)
- HIV/AIDS & Lipodystrophy & other metabolic complications (TheBody) – web site with links to many articles and fact sheets about lipodystrophy
- Body composition tests (AIDS InfoNet) and Spanish version
- Lipodystrophy and Body Changes (The Well Project)
- Lipodystrophy Treatments, Part 1: Treatments for Fat Gain (The Well Project)
- Lipodystrophy Treatments, Part 2: Treatments for Fat Loss (The Well Project)
- Excess deep gut fat and tesamorelin (Egrifta) (Project Inform) and Spanish version
- Treatment for Lipodystrophy: It’s Now the Law! What you need to know about insurance coverage for treatment of HIV-associated lipodystrophy (GLAD) – fact sheet with information about the Massachusetts law requiring public and private health insurers to cover medical treatments for HIV-associated lipodystrophy
Selected Recent Articles
Please Note: Information about fat loss from the face and other parts of the body are found on the Facial Wasting, Fat Loss, and HIV page. Information about unwanted weight loss is found on the Wasting Syndrome page.
- New State Law Requires Insurers to Cover Lipodystrophy Treatment. (August 2016, Poz)
- Few Fat or Lean Mass Differences with Raltegravir Versus Protease Inhibitors. (June 2016, TheBodyPro)
- Study Links Lipodystrophy to High Blood Pressure. (June 2016, Poz)
- Patients with HIV treated with highly active antiretroviral therapy susceptible to metabolic syndrome. (May 2016, Healio)
- Hand OA [osteoarthritis] More Prevalent With HIV Infection – Metabolic syndrome further adds to hand OA risk (April 2016, MedPage Today)
- Researchers initiate ARRIVE study for HIV-associated lipodystrophy, NAFLD. (March 2016, Healio)
- Isentress and Protease Inhibitors Lead to Similar Fat Gains. (March 2015, Poz)
- Fat Gains After Starting HIV Treatment Associated With High Viral Loads. (March 2015, TheBodyPro)
- Using raltegravir or protease inhibitors influences about equal levels of fat gains. (March 2015, Project Inform)
- Does HIV make you fat? Study connects viral load with fat gains. (March 2015, AIDSmap)
- Abdominal Body Fat Gains on ART and Viral Load: It Matters Where You Start. (March 2015, Beta Blog)
- Mood Stabilizers and Metabolic Issues [among persons living with HIV]. (August/September 2014, CATIE)
- Tesamorelin May Help HIV Patients Shed Fat. (July 2014, MedPageToday)
- Egrifta Can Reduce Abdominal and Liver Fat in People With HIV. (July 2014, Poz)
- Tesamorelin Lowers Hepatic Fat in HIV+ with Excess Visceral Fat. (March 2014, NATAP)
- Unusual and Rare HIV Complication Described in San Francisco. (December 2013, CATIE)
- Facing Facts: Dealing With Lipodystrophy. (July 2013, Poz)
- Almost three-quarters of people starting HIV therapy in Tanzania have dyslipidemia after three years of treatment. (March 2013, AIDSmap)
- The mirror has two faces. (September/October 2012, Positively Aware)
- High rate of infections in people with HIV receiving Bio-Alcamid treatment for facial lipoatrophy. (September 2012, AIDSmap)
- Reductions in visceral fat during tesamorelin therapy associated with improvements in key metabolic markers. (April 2012, AIDSmap)
- Metformin reduces artery plaque in HIV-positive people with metabolic syndrome. (March 2012, AIDSmap)
- Fat accumulation linked to cognitive impairment in patients with HIV. (February 2012, AIDSmap)
- Lipodystrophy-Related Waistline Increases Are Linked to Decreased Mental Functioning. (February 2012, Poz)
- Europeans find high prevalence of lipodystrophy in HIV-positive children. (January 2012, AIDSmap)
